Serina Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Serina Therapeutics, Inc. (SER) reported Increase Decrease In Operating Lease Liability of -$107.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- Serina Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$51.00K.
- Serina Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$56.00K.
- Serina Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$32.00K.
- Serina Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$50.00K.
- Serina Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$187.00K.
- Serina Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$214.00K.
- Serina Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$188.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$107.00K 10-Q · filed 2026-08-13 | -$139.00K derived: sum of 3 quarters · filed 2026-08-13 | -$189.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$56.00K 10-Q · filed 2026-05-14 | -$88.00K derived: sum of 2 quarters · filed 2026-05-14 | -$138.00K derived: sum of 3 quarters · filed 2026-05-14 | -$187.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$82.00K derived: sum of 2 quarters · filed 2026-03-25 | -$131.00K derived: sum of 3 quarters · filed 2026-08-13 | -$187.00K 10-K · filed 2026-03-25 |
| 2025-09-30 | -$50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$99.00K derived: sum of 2 quarters · filed 2026-08-13 | -$155.00K 10-Q · filed 2025-11-13 | -$203.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$105.00K 10-Q · filed 2026-08-13 | -$153.00K derived: sum of 3 quarters · filed 2026-08-13 | -$207.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$56.00K 10-Q · filed 2026-05-14 | -$104.00K derived: sum of 2 quarters · filed 2026-05-14 | -$158.00K derived: sum of 3 quarters · filed 2026-05-14 | -$215.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$102.00K derived: sum of 2 quarters · filed 2026-03-25 | -$159.00K derived: sum of 3 quarters · filed 2026-03-25 | -$214.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | -$54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$111.00K derived: sum of 2 quarters · filed 2025-11-13 | -$166.00K 10-Q · filed 2025-11-13 | -$222.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$112.00K 10-Q · filed 2025-08-11 | -$168.00K derived: sum of 3 quarters · filed 2025-08-11 | -$215.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$55.00K 10-Q · filed 2025-05-08 | -$111.00K derived: sum of 2 quarters · filed 2025-05-08 | -$158.00K derived: sum of 3 quarters · filed 2025-05-08 | -$199.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$103.00K derived: sum of 2 quarters · filed 2025-03-24 | -$144.00K derived: sum of 3 quarters · filed 2025-03-24 | -$188.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | -$47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$88.00K derived: sum of 2 quarters · filed 2024-11-12 | -$132.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$41.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$85.00K 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | -$44.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |